Pharma-Bio Serv, Inc. Announces Annual Meeting of Stockholders on May 2, 2024

TL;DR

<b>Pharma-Bio Serv, Inc. will hold its Annual Meeting of Stockholders on May 2, 2024, to elect directors, ratify auditors, and approve plan amendments.</b>

AI Summary

Pharma-Bio Serv, Inc. (PBSV) filed a Proxy Statement (DEF 14A) with the SEC on April 8, 2024. Annual Meeting of Stockholders scheduled for May 2, 2024, at 10:00 a.m. local time. Key agenda items include election of two Class II directors, ratification of Crowe PR PSC as independent auditors, and approval of an amendment to the 2014 Long-Term Incentive Plan. Record date for determining stockholders entitled to vote is April 3, 2024. The company's Annual Report on Form 10-K for the fiscal year ended October 31, 2023, is being mailed with the proxy statement. Meeting will be held at the law offices of Akerman LLP in Ft. Lauderdale, Florida.

Why It Matters

For investors and stakeholders tracking Pharma-Bio Serv, Inc., this filing contains several important signals. The election of directors and ratification of auditors are standard corporate governance procedures crucial for company oversight and financial integrity. Approval of amendments to the Long-Term Incentive Plan can impact future executive compensation and employee motivation, potentially influencing long-term performance.

Risk Assessment

Risk Level: low — Pharma-Bio Serv, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting with standard agenda items, indicating no immediate significant changes or concerns.

Analyst Insight

Stockholders should review the proxy materials to make informed decisions regarding director elections, auditor ratification, and incentive plan amendments.

Key Numbers

• 2 — Directors to be elected (Class II directors to serve until the 2027 Annual Meeting)
• 2027 — Director term end year (Until the 2027 Annual Meeting of Stockholders)
• 2024 — Fiscal year for auditor ratification (Fiscal year ending October 31, 2024)
• 2014 — Long-Term Incentive Plan year (Pharma-Bio Serv, Inc. 2014 Long-Term Incentive Plan)

Key Players & Entities

• Pharma-Bio Serv, Inc. (company) — Registrant name
• May 2, 2024 (date) — Date of Annual Meeting
• April 3, 2024 (date) — Record date for stockholders
• Crowe PR PSC (company) — Proposed independent certified public accountants
• Pharma-Bio Serv, Inc. 2014 Long-Term Incentive Plan (company) — Plan to be amended
• Akerman LLP (company) — Location of Annual Meeting
• Pedro J. Lasanta (person) — Chief Financial Officer, Vice President - Finance and Administration and Secretary
• October 31, 2023 (date) — Fiscal year end for 10-K report

FAQ

Key Dates

• 2024-05-02: Annual Meeting of Stockholders — Election of directors, ratification of auditors, and approval of incentive plan amendment.
• 2024-04-03: Record Date — Determines stockholders entitled to notice of and to vote at the annual meeting.
• 2024-04-08: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.

Key Financial Figures

• $12,500 — tion to our independent directors (i) a $12,500 quarterly retainer fee and (ii) an auto
• $50,000 — dividually earned and were paid fees of $50,000 each. (2) Amounts shown do not reflec

Filing Documents

• pbsv_def14a.htm (DEF 14A) — 318KB
• pbsv_def14aimg3.jpg (GRAPHIC) — 39KB
• pbsv_def14aimg4.jpg (GRAPHIC) — 36KB
• pbsv_def14aimg5.jpg (GRAPHIC) — 95KB
• pbsv_def14aimg6.jpg (GRAPHIC) — 173KB
• pbsv_def14aimg7.jpg (GRAPHIC) — 212KB
• 0001654954-24-004363.txt (&nbsp;) — 1084KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 16 PAY VERSUS PERFORMANCE 18 BENEFICIAL OWNERSHIP OF SECURITIES AND SECURITY OWNERSHIP MANAGEMENT 21 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 23

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 23 OTHER MATTERS 23 i PHARMA-BIO SERV, INC. Pharma-Bio Serv Building #6 Road 696 Dorado, Puerto Rico, 00646 PROXY STATEMENT Annual Meeting of Stockholders To be held on May 2, 2024 General We are providing these proxy materials in connection with the solicitation by the Board of Directors (the "Board") of Pharma-Bio Serv, Inc. of proxies to be voted at our 2024 Annual Meeting of Stockholders and at any and all postponements or adjournments thereof. Our Annual Meeting will be held on Thursday, May 2, 2024, at 10:00 a.m. local time at the law offices of Akerman LLP at 201 East Las Olas Boulevard, Suite 1800, Ft. Lauderdale, Florida 33301. This proxy statement and the enclosed form of proxy are first being sent to stockholders on or about April 9, 2024. In this proxy statement Pharma-Bio Serv, Inc. and its subsidiaries are referred to as the "Company," "we," "our" or "us." Purposes of the Meeting At the Annual Meeting, our stockholders will consider and vote upon the following matters: (1) The election of two directors as our Class II directors to serve for a term until the 2027 Annual Meeting of Stockholders or until his successor is duly elected and qualified (the "Election of Director Proposal"); (2) The ratification of the selection of Crowe PR PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2024 (the "Auditor Ratification Proposal"); (3) The approval of the amendment to the Pharma-Bio Serv, Inc. 2014 Long-Term Incentive Plan (the "Incentive Plan Amendment Proposal"); and (4) The transaction of such other and further business as may properly come before the meeting or any, adjournments or postponements of the meeting. Outstanding Securities and Voting Rights Only holders of record of the Company's common stock at the close of business on April 3, 2024, the record date, will be entitled to notice of, and to vote at, the Annual Meeting. On that date, we had 22,960,643

View Full Filing

View this DEF 14A filing on SEC EDGAR